In a pre-clinical study, trastuzumab-mediated ADCC of autologous peripheral blood mononuclear cells (PBMNCs) was measured by a chromium-51 release assay using a HER2-positive human breast cancer cell line (MDA-MB-361) as a target. This evidence concerns the gene ERBB2 and breast carcinoma.